Deals, Partnering

H. Lundbeck A/S Enters Into License Agreement With Kyowa Hakko Kirin For A2a Antagonists For Parkinson’s and Other Indications

Posted on 06 October 2010

Tags: , ,

Agreement with Kyowa Hakko Kirin providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356. Lundbeck will also have the right to further select compounds as either back-up or additional indication compounds 'read the full Lundbeck-Kyowa Hakko Kirin release (Link no longer available)

Print Friendly, PDF & Email

Leave a Reply